Recombinant Vaccines Market Report 2026

The recombinant vaccines market size has grown rapidly in recent years. It will grow from $15.79 billion in 2025 to $17.69 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to success of hepatitis B recombinant vaccines, historic global vaccination programs, rise in viral disease awareness, expansion of immunization funding, regulatory support for safer vaccine platforms.

The recombinant vaccines market size is expected to see rapid growth in the next few years. It will grow to $28.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to growing demand for precision vaccines, expansion of emerging disease vaccines, rising adult booster programs, increasing global immunization coverage, strong pipeline of recombinant candidates. Major trends in the forecast period include increase in recombinant subunit vaccines, expansion of vector based vaccine platforms, higher adult immunization programs, growth in combination recombinant vaccines, rising focus on long duration immunity.

The increasing prevalence of infectious diseases is expected to propel the growth of the recombinant vaccines market in the future. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that can spread from person to person directly or indirectly. The growing prevalence of infectious diseases is driven by poor sanitation and hygiene, as insufficient access to clean water, proper sanitation facilities, and effective waste management facilitates the spread of harmful microorganisms via contaminated food, water, and personal contact, increasing infection risk. Recombinant vaccines prevent infectious diseases by employing biologically engineered genetic material from pathogens to trigger an immune response without causing illness. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, over 109,000 chlamydia cases and more than 40,000 gonorrhea cases were reported as the most common sexually transmitted infections in Australia in 2023, along with over 6,400 infectious syphilis cases, highlighting the increasing prevalence and ongoing public health challenges. Therefore, the rising prevalence of infectious diseases is driving the recombinant vaccines market.

Key companies operating in the recombinant vaccines market are focusing on developing novel vaccines, such as the recombinant 9-valent HPV vaccine, to gain a competitive edge in the market. The recombinant 9-valent HPV vaccine is a vaccine that protects against nine types of human papillomavirus (HPV) and is made using recombinant DNA technology, which means it is produced in the laboratory without using live virus and helps prevent HPV-related diseases such as cervical cancer and genital warts. For example, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, advanced REC603, its recombinant 9-valent HPV vaccine, through Phase III clinical follow-up with ongoing 24-month observations. The vaccine demonstrated strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, supporting its potential for broad HPV prevention and commercialization.

In December 2025, Sanofi S.A., a France-based biopharmaceutical company, acquired Dynavax Technologies for an undisclosed amount. Through this acquisition, Sanofi intends to strengthen its adult immunization portfolio by integrating Dynavax’s marketed HEPLISAV-B recombinant hepatitis B vaccine, its phase 1/2 shingles candidate, and other pipeline assets, enhancing global vaccine development, commercial reach, and innovation in recombinant vaccines. Dynavax Technologies Corporation is a US-based company that specializes in developing and commercializing recombinant vaccines for the prevention of infectious diseases, including hepatitis B and shingles.

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

Tariffs on vaccine ingredients, bioprocess materials, and cold chain packaging are increasing production and distribution costs in the recombinant vaccines market. Import duties on adjuvants, culture media, and sterile vials are affecting subunit and vector vaccine segments. Regions dependent on cross border vaccine supply chains, particularly in developing economies, are seeing pricing and procurement challenges. Manufacturers are adjusting by regionalizing fill finish and packaging operations. Some governments are supporting local vaccine manufacturing to offset tariff effects. This is creating positive momentum for domestic vaccine facilities. It is also improving long term supply stability.

The recombinant vaccines market research report is one of a series of new reports that provides recombinant vaccines market statistics, including recombinant vaccines industry global market size, regional shares, competitors with a recombinant vaccines market share, detailed recombinant vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant vaccines industry. This recombinant vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Recombinant vaccines are immunizations produced using recombinant DNA technology, where selected genes coding for protective antigens from pathogens are introduced into safe host organisms to generate purified proteins that trigger targeted immune responses. These vaccines offer accurate, safe, and durable protection by activating immunity without exposing the body to the full pathogen, greatly lowering infection risks and side effects.

The primary types of recombinant vaccines comprise subunit vaccines and vector-based vaccines. Subunit vaccines are vaccines formulated with purified components of a pathogen, such as specific proteins, to trigger an immune response without incorporating live elements. These vaccines are developed for disease indications including human papillomavirus, herpes zoster, hepatitis B, and other diseases. They are administered through routes such as parenteral and other methods of administration and are intended for end users including pediatric and adult populations.

The recombinant vaccines market consists of sales of recombinant hepatitis B vaccines, recombinant human papillomavirus vaccines, recombinant influenza vaccines, recombinant meningococcal vaccines, recombinant dengue vaccines, recombinant malaria vaccines, and recombinant shingles vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.